A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease

Movement Disorders

Volumn 9, Issue 1, 1994, Pages 40-47

  Olanow, C W ^a   Fahn, S ^b   Muenter, M ^c   Klawans, H ^d   Hurtig, H ^e   Stern, M ^e   Shoulson, I ^f   Kurlan, R ^f   Grimes, J D ^g   Jankovic, J ^h   Hoehn, M ⁱ   Markham, C H ^j   Duvisin, R ^k   Reinmuth, O ^l   Leonard, H A ^m   Ahlskog, E ⁿ   Feldman, R ^o   Hershey, L ^p   Yahr, M D ^q  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Columbia University ^*  (United States)

^c MAYO CLINIC   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

^g UNIVERSITY OF OTTAWA   (Canada)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^m Neurological Clinic   (United States)

ⁿ MAYO CLINIC   (United States)

^o BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^q MOUNT SINAI MEDICAL CENTER   (United States)

more..

Author keywords

Levodopa; Parkinson's disease; Pergolide

Indexed keywords

ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE MESILATE;

ADULT; AGED; ARTICLE; BRADYKINESIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; FEMALE; GAIT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PERGOLIDE;

EID: 0028054876     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.870090107     Document Type: Article

References (44)

1. Effect of ergot drugs on central catecholamine neurons evidence for a stimulation of central dopamine neurons
2. Pharmacologic effects in man of a potent long‐acting dopamine receptor agonist
3. The dopaminophilic properties of ergoline derivatives
4. Interaction of pergolide with central dopaminergic receptors
5. Effects of (8B)‐8‐[(methylthio)methyl]‐6‐propylergoline on dopaminergic function and brain dopamine turnover in rats
6. Activation of adenylate in rat striatum by an ergoline dopamine agonist, pergolide
7. Pergolide, a potent long‐acting dopamine‐receptor agonist
8. The pharmacological evaluation of pergolide mesylate as a potential anti‐parkinson agent
9. Pergolide‐induced circling in rats with 6‐hydroxydopamine lesions in the nigrostriatal pathway
10. A rationale for dopamine agonists as primary therapy for Parkinson's disease
11. Kleinberg. Treatment of advanced Parkinson disease with pergolide
12. Pergolide mesylate and idiopathic Parkinson disease
13. Pergolide in late‐stage Parkinson disease
14. Pergolide therapy in Parkinson's disease a double‐blind, placebo‐controlled study
15. Double‐blind controlled study of pergolide mesylate in the treatment of Parkinson's disease
16. Parallel double‐blind study of pergolide in Parkinson's disease
17. Treatment of Parkinson's disease with pergolide a double‐blind study
18. Double‐blind trial of pergolide for Parkinson's disease
19. The effects of pergolide on the cardiovascular system of forty patients with Parkinson's disease
20. Cardiac effects of pergolide
21. Pergolide mesylate lack of cardiac toxicity in patients with cardiac disease
22. Double‐blind assessment of potential pergolide‐induced cardiotoxicity
23. The role of D‐1 and D‐2 receptors
24. Differential effects of D1 and D2 agonists in MPTP‐treated primates: functional implications for Parkinson's disease
25. D1 dopamine receptor activation required for post‐synaptic expression of D2 agonist effects
26. Bromocriptine induces marked locomotor stimulation in dopamine‐depleted mice when D‐1 dopamine receptors are stimulated with SKF38393
27. The D‐1 dopamine receptor partial agonist CY 208‐243 exhibits antiparkinsonian activity in the MPTP‐treated marmoset
28. Antiparkinsonian activity of CY 208‐243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease
29. Comparison of pergolide and bromocriptine in parkinsonism
30. Chronic agonist therapy for Parkinson's disease
31. Olanow, CW. Pergolide/parlodel crossover study
32. Dopamine agonist treatment of fluctuating parkinsonism D‐2 (Controlled‐release MK‐485) versus combined D‐1, D‐2 (pergolide)
33. Synthesis of 4‐substituted 2H‐naphth[1, 2‐b]‐1, 4‐oxazines, a new class of dopamine agonists
34. Pharmacologic profile of a novel potent direct‐acting dopamine agonist (+)‐4‐propyl‐9‐hydroxynapthththoxazine [(+)‐PHNO]
35. An introduction to the free radical hypothesis in Parkinson's disease
36. Dopamine turnover and glutathione oxidation implications for Parkinson's disease
37. Exposure of striatal synaptosomes to l‐dopa elevates levels of oxidized glutathione
38. Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture
39. Dopamine depletion protects striatal neurons from ischemia‐induced cell death
40. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of l‐dopa and carbidopa chronically
41. Administration of l‐dopa does not damage dopaminergic neurons in the mouse
42. Preservation of substantia nigra neurons and locus coeruleus in patients receiving levodopa (2 G) plus decarboxylase inhibitor over a foru‐year period
43. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease
44. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats